ASX healthcare stock Alcidion Group Ltd (ASX: ALC) is charging higher today.
Again.
Shares in the healthcare technology company closed yesterday trading for 9 cents. In morning trade on Thursday, shares are swapping hands for 9.7 cents apiece, up 7.8%. This sees the Alcidion share price up an impressive 94% since this time last year.
For some context, the All Ordinaries Index (ASX: XAO) is up 0.3% today and up 7.3% over 12 months.
Today's outperformance follows the release of the ASX healthcare stock's half-year results for the six months ending 31 December (H1 FY 2025).
Read on for the highlights.
ASX healthcare stock leaps on earnings growth
- Revenue of $17.6 million, down 7% from H1 FY 2024
- Underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $500,000, up from a loss of $2.79 million in the prior corresponding period
- Gross profit of $15.37 million, down 8% year on year
- Operating expenses of $14.3 million, down 24%
What else happened with Alcidion during the half?
Alcidion noted that the 7% decline in revenue was expected. The company said this was driven by the known reduction in non-recurring product implementation due to the near-term completion of its project implementation work for the Leidos Australia contract.
Over the half, the ASX healthcare stock signed new material contracts for its Miya Precision platform with Hume Rural Health Alliance, North Adelaide Local Health Network, and Peninsula Health.
What did management say?
Commenting on the results boosting the ASX healthcare stock today, Alcidion CEO Kate Quirke said, "Total YTD contract signings currently represent over $60M of new sales, confirming the significant value proposition of the Miya Precision platform for our customers and our shareholders."
Quirke added:
During the first half we continued to build our presence in the Australian market, particularly in Victoria, with several new contracts awarded for our leading flow and mobile solutions along with our first contract in South Australia.
The increasing challenges in efficiently moving patients through the hospital system continues to be a critical issue which hospital administrators are trying to address each and every day.
What's next for the ASX healthcare stock?
Looking at what could impact the ASX healthcare stock in the months ahead, Alcidion pointed to "strong momentum" in the second half of FY 2025, with two new sizeable contracts announced since 31 December.
"Importantly, these contracts continue to build our annual recurring revenue, which is increasingly valuable given the critical nature of our technology offering and long-standing nature of our customer relationships," Quirke said.
Alcidion said its contracted and renewal revenue currently stands at $39.5 million.
Management is confident that the ASX healthcare stock will deliver positive EBITDA and cash flow results for the full year FY 2025.
